These findings highlight the pivotal role of ASC1 UFMylation in modulating breast cancer development via ERα transactivation, presenting novel insights into the regulatory mechanisms of hormone-responsive breast cancer (42). This evidence concerns the gene TRIP4 and breast carcinoma.